Sparfloxacin for the treatment of community-acquired pneumonia: A pooled data analysis of two studies

Journal of Antimicrobial Chemotherapy

Volumn 37, Issue SUPPL. A, 1996, Pages 73-82

  Aubier, M ^a   Lode, H ^b   Gialdroni Grassi, G ^c   Huchon, G ^d   Hosie, J ^e   Legakis, N ^f   Regamey, C ^g   Segev, S ^h   Vester, R ⁱ   Wijnands, W J ^j   Tolstuchow, N ^k  

^a BICHAT HOSPITAL   (France)

^b MARTIN LUTHER KRANKENHAUS   (Germany)

^c UNIVERSITY OF PAVIA   (Italy)

^d HÔPITAL AMBROISE PARÉ   (France)

^e GREAT WESTERN HOSPITAL   (United Kingdom)

^f UNIVERSITY OF ATHENS   (Greece)

^g Hopital Cantonal de Fribourg   (Switzerland)

^h SHEBA MEDICAL CENTER   (Israel)

ⁱ Leslie Williams Memorial Hospital   (South Africa)

^j DEVENTER HOSPITAL   (Netherlands)

^k HÔTEL DIEU   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; ERYTHROMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PNEUMONIA;

EID: 9344237643     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/37.suppl_a.73     Document Type: Article

References (22)

1. Dabernat, H., Delmas, C., Seguy, M. & Lareng, M. B. (1991). Comparative in vitro activity of sparfloxacin against Haemophilus influenzae and Branhamella catarrhalis. European Journal of Clinical Microbiology and Infectious Diseases Special Issue, 544-5.
2. Farr, B. M., Kaiser, D. L., Harrison, B. D. W. & Connolly, C. K. (1989). Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. Thorax 44, 1031-5.
3. Friedland, I. R. & McCracken, G. H. (1994). Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. New England Journal of Medicine 331, 377-82.
4. Genevois, E., Lelouer, V., Vercken, J.-B. & Caillon, R. (1996). Study design, methodology and statistical analyses in the clinical development of sparfloxacin. Journal of Antimicrobial Chemotherapy 37, Suppl. A, 65-72.
5. Geslin, P., Fremaux, A., Sissia, G., Spicq, C. & Aberrane, S. (1994). Epidémiologie de la résistance aux antibiotiques de Streptococcus pneumoniae en France. Réseau national de surveillance (1984-1993). Médecine et Maladies Infectieuses 24, 948-61.
6. Hammerschlag, M. R., Hyman, C. L. & Roblin, P. M. (1992). In-vitro activity of five quinolones against C. pneumoniae. Antimicrobial Agents and Chemotherapy 36, 682-3.
7. Harrison, B. D. W., Farr, B. M., Connolly, C. K., MacFarlane, J. T., Selkon, J. B. & Bartlett, C. L. R. (1987). The hospital management of community-acquired pneumonia. recommendations of the British Thoracic Society. Journal of the Royal College of Physicians of London 21, 267-9.
8. Honeybourne, D., Greaves, I., Baldwin, D. R., Andrews, J. M., Harris, M. & Wise, R. (1994). The concentration of sparfloxacin in lung tissues after single and multiple oral doses. International Journal of Antimicrobial Agents 4, 151-5.
9. Huchon, G. J., Gialdroni-Grassi, G., Léophonte, P., Manresa, F. & Woodhead, M. (1994). First line therapy for community acquired pneumonia (CAPD) by general practitioners in five European countries. European Respiratory Journal 7, Suppl. 18, 1994. Abstract 1273, p. 271S. European Respiratory Society Annual Congress. Nice, France.
10. Jacoby, G. A. (1994). Prevalence and resistance mechanisms of common bacterial respiratory pathogens. Clinical Infectious Diseases 18, 951-7.
11. Jones, R. N. & Barry, A. L. (1991). Activity of sparfloxacin (AT-4140), PD-127391 and PD-131628 against Legionella spp. Journal of Antimicrobial Chemotherapy 27, 389-96.
12. Kayser, F. H., Morenzoni, G. & Santanam, P. (1990). The Second European Collaborative Study on the frequency of antimicrobial resistance in Haemophilus influenzae. European Journal of Clinical Microbiology and Infectious Diseases 9, 810-17.
13. Kemper, C. A. & Deresinski, S. C. (1991). Diagnosis and management of pneumonia. Pharmacotherapy 11, Part. 2, 84-9.
14. Léophonte, P., Mularczyk, M. & Geslin, P. (1993). Pneumonies à pneumocoques résistants. Presse Médicale 22, 914-8.
15. Lode, H. and European Study Group. (1996). Treatment of community-acquired pneumonia: a multicenter prospective double blind randomized study in 808 patients comparing sparfloxacin with amoxycillin-clavulanic acid or erythromycin. European Respiratory Journal, in press.
16. Mayaud, C., Parrot, A., Houacine, S., Denis, M. & Akoun, G. (1992). Epidémiologie des germes responsables au cours des pneumopathies communautaires. Revue de Pneumologie Clinique 48, 101-10.
17. Nilsen, O. G. (1987). Comparative pharmacokinetics of macrolides. Journal of Antimicrobial Chemotherapy 20, Suppl. B, 81-8.
18. Perea, E. J., Garcia-Iglesisas, M. C. & Clavijo, M. J. (1991). Abstract 133. In Program and Abstracts of the Thirtieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 1991. American Society for Microbiology, Washington, DC.
19. Quatrième Conférence de Consensus en thérapeutique anti-infectieuse de la Société de Pathologie Infectieuse de Langue Française. Lille-France (1991). Les infections des voies respiratoires. Médecine et Maladies Infectieuses, Suppl. 21, 1-8.
20. Renaudin, H. & Bebear, C. (1992). Activité in vitro de la sparfloxacine sur les mycoplasmes. Pathologie Biologie 40, 450-4.
21. Rubinstein, E. (1996). Safety profile of sparfloxacin in the treatment of respiratory tract infections. Journal of Antimicrobial Chemotherapy 37, Suppl. A, 145-60.
22. Verbist, L. & Verhaegen, J. (1990). Comparative in-vitro activity of sparfloxacin (AT-4140) against respiratory pathogens. In Program and Abstracts of the Thirtieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, 1990. Abstract 16. American Society for Microbiology, Washington, DC.